glutamine has been researched along with candesartan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fujita, T; Hirooka, K; Itano, T; Nagai, Y; Nakamura, T; Nishiyama, A; Shiraga, F | 1 |
1 review(s) available for glutamine and candesartan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for glutamine and candesartan
| Article | Year |
|---|---|
Neuroprotective effects of angiotensin II type 1 receptor (AT1-R) blocker via modulating AT1-R signaling and decreased extracellular glutamate levels.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cell Survival; Disease Models, Animal; Electroretinography; Extracellular Fluid; Gene Expression Regulation; Glutamine; Immunohistochemistry; Male; NADPH Oxidases; Phosphoproteins; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Reperfusion Injury; Retina; Retinal Diseases; Retinal Ganglion Cells; RNA, Messenger; Signal Transduction; Tetrazoles; Vitreous Body | 2012 |